BRANDON A. WUSTMAN, Ph.D.

Senior Vice President, R&D

Dr. Wustman is a seasoned R&D executive with experience throughout his nearly 20-year career across many phases of R&D including discovery, clinical development, and the launch of new therapeutic platforms.

Prior to joining ReCode Therapeutics (and its predecessor, TranscripTx) in 2015, he had positions of increasing responsibility, including Senior Director, Preclinical Biology, at Amicus Therapeutics from 2002 to 2014.  At Amicus, Dr. Wustman established a new lab focused on protein therapeutic discovery and production.  He was also instrumental in leading the discovery and preclinical development of pharmacological chaperones used alone and in combination with enzyme replacement therapies for seven different preclinical programs.

Dr. Wustman received his B.S. and Ph.D. from Michigan Technological University.  He was an Alexandar Humboldt Fellow at the University of Cologne, Germany and a postdoctoral fellow at New York University from 2000 to 2002. Dr. Wustman has published more than 20 peer-reviewed scientific articles and is also the inventor on nine issued U.S. patents.